An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Celyad Oncology Announces September 2021 Conferences Schedule
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Celyad Oncology SA (Brussels:CYAD) announced its participation in several conferences in September 2021, including the Wells Fargo Virtual Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird’s Virtual Global Healthcare Conference. CEO Filippo Petti will present at these events, highlighting the company's focus on developing CAR T cell therapies for cancer. Celyad is based in Belgium and has received funding from the Walloon Region to support its initiatives. Further details can be found on their website.
Positive
Participation in multiple significant healthcare conferences, showcasing potential investor and market engagement.
Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021:
2021 Wells Fargo Virtual Healthcare Conference Dates: Thursday, September 9 – Friday, September 10, 2021 Presentation date: Thursday, September 9 Time: 11:20 a.m. ET / 05:20 p.m. CET Presenter: Filippo Petti, CEO
A webcast link will be available on the Events section of the Celyad Oncologywebsite.
H.C. Wainwright 23rd Annual Global Investment Conference Dates: Monday, September 13 - Wednesday, September 15, 2021
Presentation: On-demand starting September 13, 7 a.m. ET / 1 p.m. CET Presenter: Filippo Petti, CEO
Baird’s 2021 Virtual Global Healthcare Conference Dates: Tuesday, September 14 – Wednesday, September 15, 2021 Presentation date: Tuesday, September 14 Time: 3:45 p.m. ET / 9:45 p.m. CET Presenter: Filippo Petti, CEO
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Forward-Looking Statement
This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
What conferences is Celyad Oncology attending in September 2021?
Celyad Oncology is participating in the Wells Fargo Virtual Healthcare Conference, H.C. Wainwright Global Investment Conference, and Baird’s Virtual Global Healthcare Conference in September 2021.
Who will present for Celyad Oncology at the upcoming conferences?
CEO Filippo Petti will present at the upcoming conferences.
What is the focus of Celyad Oncology's business?
Celyad Oncology focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer.
Where is Celyad Oncology located?
Celyad Oncology is based in Mont-Saint-Guibert, Belgium, and New York, NY.
